We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 3 for:    roadsaver

Evaluation of the Roadsaver Stent Used in Conjunction With the Nanoparasol Embolic Protection System for Carotid Artery Stenosis

This study is currently recruiting participants.
Verified January 2017 by Microvention-Terumo, Inc.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02657707
First Posted: January 18, 2016
Last Update Posted: January 31, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Microvention-Terumo, Inc.
  Purpose
A prospective, multicenter, single-arm, open label clinical study to evaluate the safety and effectiveness of MicroVention, Inc. Roadsaver™ Carotid Stent System used in conjunction with the Nanoparasol® embolic protection system for the treatment of carotid artery stenosis in patients with elevated risk for adverse events following carotid endarterectomy.

Condition Intervention
Carotid Artery Stenosis Device: Roadsaver™ Carotid Artery Stent Device Device: Nanoparasol® Embolic Protection System

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pivotal Study of the MicroVention, Inc. Carotid Artery Stent System Used in Conjunction With the Nanoparasol® Embolic Protection System for the Treatment of Carotid Artery Stenosis in Patients at Elevated Risk for Adverse Events From Carotid Endarterectomy.(CONFIDENCE Trial)

Further study details as provided by Microvention-Terumo, Inc.:

Primary Outcome Measures:
  • All stroke, death, and MI [ Time Frame: At 30 days ]
  • Ipsilateral stroke [ Time Frame: At 12 months ]

Secondary Outcome Measures:
  • Successful deployment of stent [ Time Frame: Procedure day ]
  • Successful completion of procedure [ Time Frame: Procedure day ]
  • Successful deployment and retrieval of embolic protection device [ Time Frame: Procedure day ]
  • Target lesion revascularization (TLR) [ Time Frame: At 6 and 12 months ]
  • In-stent restenosis [ Time Frame: At 6 and 12 months ]
  • Major stroke [ Time Frame: At 30 days ]
  • Minor stroke [ Time Frame: At 30 days ]
  • Transient ischemic attack (TIA) [ Time Frame: Within 30 days ]
  • Neurologic death [ Time Frame: At 12 months ]

Estimated Enrollment: 295
Study Start Date: April 2016
Estimated Study Completion Date: August 2020
Estimated Primary Completion Date: August 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Single-arm, open label
To evaluate the safety and effectiveness of MicroVention, Inc. Roadsaver™ Carotid Stent System used in conjunction with the Nanoparasol® embolic protection system for the treatment of carotid artery stenosis in patients with elevated risk for adverse events following carotid endarterectomy.
Device: Roadsaver™ Carotid Artery Stent Device
The Roadsaver™ carotid artery stent system is indicated for use in patients with significant atherosclerotic disease of the carotid arteries.
Device: Nanoparasol® Embolic Protection System
The Nanoparasol® embolic protection system is indicated for use with a guidewire to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in carotid arteries.

Detailed Description:

A total of 295 patients will be enrolled for this study. All potential patients being considered for the study should have been diagnosed with significant carotid artery stenosis and be considered a high perioperative risk for carotid endarterectomy.

Patients will be evaluated through screening, pre-procedure, index procedure, post-procedure. Follow-up visits will be completed at 30 days, 6 months, and 12, 24, and 36 months post-procedure.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patient is between >21 and ≤80 years of age.
  2. Patient is willing and capable of complying with all study protocol requirements, including specified follow-up period and can be contacted by telephone.
  3. Patient or authorized legal representative is willing to provide written informed consent prior to enrollment in study.
  4. Patient should have been diagnosed with carotid artery stenosis and be considered a high operative risk for carotid endarterectomy.
  5. Patient is either:

    • Symptomatic with carotid stenosis ≥50% as determined by angiography using NASCET methodology. Symptomatic is defined as amaurosis fugax ipsilateral to the carotid lesion; TIA or non-disabling stroke within 180 days of the procedure within the hemisphere supplied by the target vessel; or
    • Asymptomatic with carotid stenosis ≥80% as determined by angiography using NASCET methodology.
  6. Patient has a target lesion located at the carotid bifurcation and/or proximal ICA.
  7. Patient has a single de novo or restenotic (post CEA) target lesion or severe tandem lesions close enough that can be covered by a single Roadsaver™ stent.
  8. Patients having a vessel with reference diameters between 3.0 mm and 9.0 mm at the target lesion.

High Risk Inclusion Criteria

For inclusion in the study, a patient must qualify in at least one anatomic or co-morbid high-risk condition, as shown below:

Anatomic High Risk Conditions:

  1. Patient has a target lesion at or above the second vertebral body (level of jaw) or below the clavicle.
  2. Patient has an inability to extend the head due to cervical arthritis or other cervical disorders.
  3. Patient is status/post radiation therapy to the neck.
  4. Patient has a prior head and neck surgery in the region of the carotid artery.
  5. Patient has spinal immobility of the neck.
  6. Patient has the presence of tracheostomy stoma.
  7. Patient has laryngeal palsy or laryngectomy.
  8. Patient has a hostile neck or surgically inaccessible lesion.
  9. Patient has severe tandem lesions.

Co-morbid High Risk Conditions:

  1. Patient is ≥70 years of age (maximum 80 years) at the time of enrollment.
  2. Patient has NYHA Class III or IV congestive heart failure (CHF) with FEV <35%.
  3. Patient has chronic obstructive pulmonary disease (COPD).
  4. Patient has a left ventricular ejection fraction (LVEF) <35%.
  5. Patient has unstable angina.
  6. Patient has had a recent myocardial infarction (≥30 days prior to stenting procedure).
  7. Patient has coronary artery disease with two or more vessels with ≥ 70% stenosis.
  8. Patient has planned CABG or valve replacement surgery between 31‐60 days after the CAS procedure.
  9. Patient requires peripheral vascular surgery or abdominal aortic aneurysm repair between 31‐60 days following the CAS procedure.
  10. Patient has contralateral laryngeal nerve paralysis
  11. Patient has restenosis after a previous CEA.

Exclusion Criteria:

  1. Patient has life expectancy of less than one year.
  2. Patient is experiencing (or has experienced) an evolving, acute, or recent disabling stroke in the last 30 days.
  3. Patient has anticipated or potential sources of emboli (e.g. known previously symptomatic patent foramen ovale (PFO), mechanical heart valve, or deep vein thrombosis (DVT) treated within 6 months) that are not adequately treated with anticoagulants for at least two weeks with documented coagulation parameters in the target therapeutic range.
  4. Patient has atrial fibrillation.
  5. Patient has had an acute myocardial infarction within 60 days prior to index procedure.
  6. Patient has had or plans to have any major surgical procedure (i.e. intraabdominal or intrathoracic surgery or any surgery/interventional procedure involving cardiac or vascular system) within 30 days of the index procedure.
  7. Patient has a history of major ipsilateral stroke.
  8. Patient has known severe carotid stenosis or complete occlusion contralateral to the target lesion requiring treatment within 30 days following the index procedure.
  9. Patient has a modified Rankin Scale of >2 or has another neurological deficit not due to stroke that may confound the neurological patient assessments.
  10. Patient has chronic renal insufficiency (serum creatinine ≥2.5 mg/dL) or has a history of severe hepatic impairment, malignant hypertension, and/or is morbidly obese.
  11. Patient has platelet count <100,000/μL.
  12. Patient has known sensitivity to heparin or previous incidence of Heparin‐Induced Thrombocytopenia (HIT) type II.
  13. Patient has contraindication to standard of care study medications, including antiplatelet therapy.
  14. Patient has known sensitivity to contrast media that cannot be adequately controlled with premedication.
  15. Patient has known bleeding diathesis or hypercoagulable state or refuses blood transfusions.
  16. Patient has intracranial pathology that, in the opinion of the investigator, makes the patient inappropriate for study participation (e.g. brain tumor, AVM, cerebral aneurysm, cerebral vascular disease [microangiopathy or large vessel], etc.) or would confound neurological evaluation.
  17. Patient had intracranial hemorrhage within the last 90 days.
  18. Patient is currently enrolled in another investigational study protocol and has not completed its primary endpoint or that will confound the current study endpoints. Patients who are involved in the long‐term surveillance of a clinical study are eligible.
  19. Patient suffers from confusion or dementia or is unable or unwilling to cooperate with the study requirements and/or follow‐up procedures.
  20. Patient has a known, unresolved history of drug use or alcohol dependency.
  21. Patient has an active infection.
  22. Patient has renal failure and/or is on dialysis.
  23. Patient has documented uncontrolled diabetes.
  24. Patient is pregnant.

Angiographic Exclusion Criteria

A patient is not eligible for enrollment in the study if he/she meets any of the following angiographic exclusion criteria:

  1. Patient has a total occlusion of the target carotid arteries (i.e., CCA or ICA).
  2. Patient has a previously placed stent in the ipsilateral carotid artery.
  3. Patient has severe lesion calcification or vascular tortuosity that may preclude the safe introduction of the sheath, guiding catheter, embolic protection system, or stent.
  4. Patient has the presence of mobile filling defect or thrombus in target vessel.
  5. Patient has occlusion or presence of "string sign" of the target vessel.
  6. Patient has carotid (intracranial) stenosis located distal to target stenosis that is more severe than target stenosis.
  7. Patient has known mobile plaque or thrombus in the aortic arch.
  8. Patient has a type III aortic arch.
  9. Patient in whom femoral access is not possible.
  10. Patient has arteriovenous malformations of the territory of the target carotid artery.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02657707


Contacts
Contact: Amy Walters 714.247.8000 amy.walters@microvention.com
Contact: David Nguyen 714.247.8000 david.nguyen@microvention.com

  Show 34 Study Locations
Sponsors and Collaborators
Microvention-Terumo, Inc.
Investigators
Principal Investigator: Adnan Siddiqui, MD University of Buffalo - Neurosurgery
Principal Investigator: Chris Metzger, MD Wellmont CVA Heart Institute
Principal Investigator: Peter Schneider, MD Kaiser Permanente Moanalua Medical Center
  More Information

Responsible Party: Microvention-Terumo, Inc.
ClinicalTrials.gov Identifier: NCT02657707     History of Changes
Other Study ID Numbers: CL11003
First Submitted: January 11, 2016
First Posted: January 18, 2016
Last Update Posted: January 31, 2017
Last Verified: January 2017

Keywords provided by Microvention-Terumo, Inc.:
stent
stenosis
artery
carotid

Additional relevant MeSH terms:
Constriction, Pathologic
Carotid Stenosis
Pathological Conditions, Anatomical
Carotid Artery Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases